Volume 14 Supplement 4

International Conference ‘Advances in Pneumology’

Open Access

Expression of anti-apoptotic protein survivin and tumor suppressor p53 protein in patients with pulmonary carcinoma

  • E Halasová1,
  • M Adamkov2Email author,
  • E Kavcová3,
  • T Matáková4,
  • L Musák1,
  • D Vybohová5,
  • M Janícková6,
  • D Mistuna7 and
  • A Singliar8
European Journal of Medical Research200914(Suppl 4):97

https://doi.org/10.1186/2047-783X-14-S4-97

Published: 7 December 2009

Abstract

Background

Survivin is one of the inhibitors of the apoptosis gene family that has been implicated in both inhibition of apoptosis and mitosis regulation. p53 is one of the tumor suppressor genes; prevents tumor formation through cell cycle blocking and eliminates damaged cells via activation of apoptosis.

Objective

To investigate the possible regulation of survivin by p53, we examined the expression of both proteins in 67 patients with diagnosed lung cancer using immunohistochemical visualization.

Results

Survivin was predominantly expressed in both nucleus and cytoplasm, whereas p53 was expressed in the nucleus. There was a negative correlation between survivin and p53 expression. A decreased intensity of expression and fewer cells positive for survivin in small cell lung cancer in comparison with other lung cancer types were detected. There was no significant difference in the intensity of expression and the number of cells positive for p53 between small cell and non-small cell lung cancer types.

Conclusion

The present study suggests that survivin expression, as opposed to that of p53, is decreased in small cell lung cancer, which may differentiate this cancer from other lung cancer types other types.

Keywords

immunohistochemistry lung cancer p53 survivin

Introduction

Apoptosis or programed cell death is needed for the maintenance of cell homeostasis and to destroy cells that represent a threat to the integrity of an organism. Apoptosis can be induced by either specific extracellular signals or internal stimuli. The molecular mechanisms involved in apoptotic enzymatic pathway have been sufficiently reviewed [1]. The protein p53 plays an important role in apoptosis induction. It acts as a transcription factor which is in humans encoded by the TP53 gene [2, 3]. p53 is activated by various stress signals as radiation (UV, gamma, or X-ray), carcinogens (polycyclic aromatic carbohydrates, heavy metals), oxidative stress, hypoxia, oncogene activation, telomere, and others [4]. Apoptosis induction is one of the main functions of p53. Many genes are involved in p53 dependent apoptotic pathways. Based on the pathways involved, the pro-apoptotic genes can be classified into three main groups:
  1. 1.

    Genes for 'death receptor family'. p53 can induce apoptosis through activation of death receptors, such as Apo-1, DR4 and DR5;

     
  2. 2.

    Genes involved in internal apoptotic pathway. This pathway is activated by stress factors and mediated by mitochondrion. Proteins of Bcl-2 family play the main function in this pathway. In p53-mediated apoptosis BAX, PUMA, and Noxa proteins are involved. Bcl-2 is an anti-apoptotic protein inhibited by p53;

     
  3. 3.

    Other target genes. Many other members of the apoptotic machinery can be activated though p53 in apoptosis inducted by DNA damage, such as Apaf-1 or caspase 6 [58].

     

The expression and activity of p53 is precisely regulated at many levels [9]. p53 prevents tumor formation through cell cycle blocking and eliminates damaged cells. Mutations or inactivation of p53 are the most frequent changes in human tumorous cells [10]. On the other hand, survivin is an inhibitor of the apoptosis (IAP) gene family, which has been implicated in both inhibition of apoptosis and mitosis regulation [11]. Survivin upregulates genes in tumor tissues [12]. High survivin expression is related to poor prognosis in many cancer types [13, 14] Some investigations have shown that p53 leads to the repression of survivin in non-small lung cancers [15]. There are many studies pointing to the expression of the proteins mentioned in non-small cell lung cancers, but only few in small cell carcinomas [1618]. Therefore, in the present study, we examined the expression and correlation of p53 and survivin in different lung cancer cells.

Materials and methods

An institutional Ethics Committee approved the protocol of this study. One hundred samples obtained from operated pulmonary carcinoma patients were evaluated for survivin and p53 expression. Sixty seven of them were enrolled into the study. The remaining cases had to be excluded because of specimens' damage. Hematoxylin and eosin stained slides from each case were independently reviewed by two pathologists to ascertain the diagnosis based on morphological and immunohistochemical parameters and were correlated with clinical data. Three sections, 4 μm thick, obtained from each paraffin block, were stained for p53 and survivin proteins. To achieve greater adherence of sections to glass surface, silanized slides (DAKO, Denmark) were used, kept in an oven for 2 h at 56°C. Then, the sections were deparaffinized in xylene for 20 min, rehydrated in a series of descending ethanol concentrations, and washed with phosphate-buffered saline (PBS). Endogenous peroxidase activity was blocked with 3% H2O2 for 30 min. Antigen unmasking was achieved by heating the sections, immersed in a target solution (DAKO), in a hot water bath (96°C) for 45 min. Immunohistochemical staining was performed using monoclonal mouse anti-p53 antibody (DAKO, Clone DO-7, dilution 1:50) and monoclonal mouse anti-survivin antibody (DAKO, Clone12C4, dilution 1:50). After overnight incubation, the p53 and survivin antigens were visualized with an LSAB Visualization System (DAKO) using 3,3'-diaminobenzidine chromogen as a substrate, according to manufacturer's instructions. All sections were counterstained with Mayer's hematoxylin (DAKO). Negative controls were obtained by simple omitting the primary antibodies.

Evaluation of Immunohistochemical Staining

Survivin and p53 antibody stained sections were examined under light microscopy and the positivity of their expression was determined semi-quantitatively. In each case, the following features were assessed: (i) intensity of staining scored as absent (0), weak (+), moderate (++), and strong (+++); (ii) relative number of positively stained cells: more or less than 25% (≥ 25 or ≤ 25%) per field of view; and (iii) subcellular localization of p53 and survivin antigens: nuclear (N), cytoplasmic (C), or both (NC).

Statistical Analysis

Chi-square (χ2) test or Fischer's exact test was used for the statistical analysis to compare the observed parameters between survivin and p53 immunoreactivity. Spearman's coefficient was used to estimate the correlation between parameters. All statistical calculations were performed using Microsoft Excel and MedCalc v.5 software for Windows.

Results

The results of the expression profiling are summarized in Table 1 and illustrated in Figure 1 (Panels A and B). Survivin was predominantly expressed in both nucleus and cytoplasm in 58 (97%) of cases (Figure 1A), whereas p53 was in the nucleus alone in 56 (89%) of cases (Figure 1B). A majority of cases (61; 92%) showed ≥ 25% of positively stained cells for p53 compared with just 18 cases (29%) with ≥ 25% of positively stained cells per field of view for surviving; the difference was significant - χ2 = 53.8; P < 0.001). There was a negative correlation (r = -0.72) between the survivin and p53 expressions. It seems that p53 down-regulated the expression of survivin. A comparison of non-small and small cell lung cancer types for survivin expression showed a significant decrease in the intensity and a fewer number of positive cells in small cell lung cancer (χ2 = 15.3; P < 0.001 and χ2 = 8.4; P < 0.05, respectively). In contrast, the expression and the number of cells positive for p53 did not differ significantly between small cell and non-small cell lung cancer types.
Table 1

Expression of survivin and p53 in 67 biopsies from patients with lung cancer.

 

I

%

SL

 

0

+

++

++

< 25

> 25

N

C

NC

Survivin

7

20

32

8

43

18

1

1

58

p53

4

13

29

21

5

61

56

1

6

I - intensity of immunoreactivity: (+) weak, (++) moderate, (+++) strong; % - percent of labeled cells;

SL - subcellular localization: N-nuclear, C-cytoplasmic, NC-nuclear and cytoplasmic.

Figure 1

Panel A - Combined cytoplasmic and nuclear survivin immunopositivity in tumor cells (primary magnification - 600×); Panel B - Nuclear p53 immunopositivity in tumor cells (primary magnification - 400×).

Discussion

p53 is a multifunctional protein that regulates cell division and activates apoptosis. On the other hand, survivin can act as an apoptosis inhibitor, being overexpressed in many malignancies, including lung carcinoma. A lot of studies have been focused on the relationship between survivin and p53 expression, but the results have been quite controversial. Jin et al. [16] suggested that survivin expression is negatively regulated by p53. Nakano et al. [17] investigated survivin and p53 expression in specimens from 140 non-small cell lung cancer patient. They found significant differences in survivin expression in squamose cell carcinomas and adenocarcinomas. Furthermore, survivin expression in tumors with mutant p53 was significantly higher than that in tumors with a wild-type p53. The authors concluded that the survivin gene expression is negatively regulated by p53 in NSCLC, which can inhibit apoptosis and accelerate tumor proliferation to produce more aggressive carcinomas. The findings of the present study are in accord with those results. We found a negative correlation between p53 and survivin expressions, which confirms a relationship between these two opposite proteins. However, opposing results were published by Akjurek et al. [18]. The aim of those authors' immunohistochemical study was to investigate the role of survivin in the early steps of lung carcinogenesis and non-small cell carcinomas, and its relation to the expression of p53. They found no correlation between survivin and p53 expressions, although the patients in whom survivin was expressed had a significantly worse prognosis.

Molecular mechanisms of tumor progression and apoptosis are still unclear. Several predictors, such as nodal involvement, tumor stage, and surviving and p53 expressions have been reported; however, the relationship between p53 or survivin and the prognosis of lung cancer patients is still controversial [1921]. The present study calls attention to the expression of survivin in relation to p53 in small cell lung carcinoma, suggesting that survivin expression is decreased in this cancer type compared with other types. Further studies are required to explain and understand these findings.

Conflicts of interest

The authors declare that they have no competing interests.

Declarations

Acknowledgements

Supported by MZ 2007/48-UK-13 and AV 4/2026/08 Grants.

Authors’ Affiliations

(1)
Institute of Medical Biology, Jessenius Faculty of Medicine, Comenius University Martin
(2)
Institute of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University Martin
(3)
Clinics of Pneumophthisiology, Jessenius Faculty of Medicine, Comenius University Martin
(4)
Institute of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University Martin
(5)
Institute of Anatomy, Jessenius Faculty of Medicine, Comenius University Martin
(6)
Clinics of Stomatology and Maxillofacial Surgery, Jessenius Faculty of Medicine, Martin and Faculty Hospital in Martin, Comenius University
(7)
Clinics of Surgery, Jessenius Faculty of Medicine, Martin and Faculty Hospital in Martin, Comenius University
(8)
Department of Pathology, Hospital in Dolny Kubín

References

  1. Jinz Z, El-Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther 2005, 4: 139–163. 10.4161/cbt.4.2.1508Google Scholar
  2. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S: Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J 1984, 3: 3257–3262.PubMed CentralPubMedGoogle Scholar
  3. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumor antigen to band 17p13. Nature 1986, 320: 84–85. 10.1038/320084a0PubMedView ArticleGoogle Scholar
  4. Pluquet O, Hainaut P: Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 2001, 174: 1–15. 10.1016/S0304-3835(01)00698-XPubMedView ArticleGoogle Scholar
  5. Moll UM, Zaika A: Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett 2001, 493: 65–69. 10.1016/S0014-5793(01)02284-0PubMedView ArticleGoogle Scholar
  6. Schuler M, Green D: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001, 29: 36–42.Google Scholar
  7. Pietenpol JA, Stewardt ZA: Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology 2002, 181: 475–481.PubMedView ArticleGoogle Scholar
  8. Yu J, Zhang L: The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005, 331: 851–858. 10.1016/j.bbrc.2005.03.189PubMedView ArticleGoogle Scholar
  9. Coutts AS, Thangue N: The p53 response during DNA damage: impact of transcriptional cofactors. Biochem Soc Symp 2006, 73: 181–189.PubMedGoogle Scholar
  10. Deng Y, Wu X: Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA 2000, 97: 12050–12055. 10.1073/pnas.97.22.12050PubMed CentralPubMedView ArticleGoogle Scholar
  11. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3: 46–54. 10.1038/nrc968PubMedView ArticleGoogle Scholar
  12. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW, et al.: Analysis of human transcriptomes. Nat Genet 1999, 32: 387–388.View ArticleGoogle Scholar
  13. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58: 179–185.Google Scholar
  14. Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K: Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007, 27: 2803–2808.PubMedGoogle Scholar
  15. Mirza A, McGuirk M, Hockenberry TN, et al.: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogen 2002, 21: 2613–2622. 10.1038/sj.onc.1205353View ArticleGoogle Scholar
  16. Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH, Yoo DH, Lee SJ, Choe TB, An S, Kwon TJ, Kim JI, Park MJ, Hong SI, Park IC, Rhee CH: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 2006, 7210: 1228–1236.View ArticleGoogle Scholar
  17. Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H: Survivin gene expression is negatively regulated by p53 tumor supressor gene in non-small cell lung cancer. Int J Oncol 2005, 27: 1215–1221.PubMedGoogle Scholar
  18. Akyürek N, Memis L, Ekinci O, Köktürk N, Oztürk C: Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 2006, 449: 164–170. 10.1007/s00428-006-0239-9PubMedView ArticleGoogle Scholar
  19. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000, 6: 4055–4063.PubMedGoogle Scholar
  20. Fan J, Wang L, Jiang GN, He WX, Ding JA: The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008, 61: 91–96. 10.1016/j.lungcan.2007.11.011PubMedView ArticleGoogle Scholar
  21. Yamashita S, Chujo M, Miyawaki M, Tokuishi K, Anami K, Yamamoto S, Kawahara K: Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J Exp Clin Cancer Res 2009, 28: 22. 10.1186/1756-9966-28-22PubMed CentralPubMedView ArticleGoogle Scholar

Copyright

© I. Holzapfel Publishers 2009